TSPO PET Identifies Different Anti-inflammatory Minocycline Treatment Response in Two Rodent Models of Epileptogenesis

Neurotherapeutics. 2020 Jul;17(3):1228-1238. doi: 10.1007/s13311-020-00834-5.

Abstract

Epileptogenesis-associated brain inflammation might be a promising target to prevent or attenuate epileptogenesis. Positron emission tomography (PET) imaging targeting the translocator protein (TSPO) was applied here to quantify effects of different dosing regimens of the anti-inflammatory drug minocycline during the latent phase in two rodent models of epileptogenesis. After induction of epileptogenesis by status epilepticus (SE), rats were treated with minocycline for 7 days (25 or 50 mg/kg) and mice for 5 or 10 days (50 or 100 mg/kg). All animals were subjected to scans at 1 and 2 weeks post-SE. Radiotracer distribution was analyzed and statistical parametric mapping (SPM) was performed, as well as histological analysis of astroglial activation and neuronal cell loss. Atlas-based analysis of [18F]GE180 PET in rats revealed a dose-dependent regional decrease of TSPO expression at 2 weeks post-SE. Results of SPM analysis depicted a treatment effect already at 1 week post-SE in rats treated with the higher minocycline dose. In mice, TSPO PET imaging did not reveal any treatment effects whereas histology identified only a treatment-related reduction in dispersion of dentate gyrus neurons. TSPO PET served as an auspicious tool for temporal monitoring and quantification of anti-inflammatory effects during epileptogenesis. Importantly, the findings underline the need to applying more than one animal model to avoid missing treatment effects. For future studies, the setup is ready to be applied in combination with seizure monitoring to investigate the relationship between individual early treatment response and disease outcome.

Keywords: Neuroinflammation; PET; epileptogenesis; minocycline; translocator protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / metabolism*
  • Anti-Inflammatory Agents / therapeutic use
  • Brain / diagnostic imaging
  • Brain / drug effects
  • Brain / metabolism
  • Carrier Proteins / metabolism*
  • Disease Models, Animal
  • Epilepsy / diagnostic imaging
  • Epilepsy / drug therapy
  • Epilepsy / metabolism*
  • Female
  • Male
  • Mice
  • Minocycline / metabolism*
  • Minocycline / therapeutic use
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, GABA-A / metabolism*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Carrier Proteins
  • Radiopharmaceuticals
  • Receptors, GABA-A
  • Tspo protein, rat
  • Minocycline